S. Shepard

发表

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

H. Kantarjian, T. Manshouri, A. Quintás-Cardama, 2010, Blood.

Metathesis approach to the synthesis of polyheterocyclic structures from oxanorbornenes.

J. Winkler, S. Shepard, S. Asselin, 2004, Organic letters.

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream

M. Covington, S. Shepard, S. Yeleswaram, 2021, Pharmaceutics.

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

J. Fridman, Jun Li, X. Wen, 2010, The Journal of Immunology.

Selective Inhibition of JAK 1 and JAK 2 Is Efficacious in Rodent Models of Arthritis : Preclinical Characterization of INCB 028050

J. Fridman, Jun Li, X. Wen, 2010 .

Preclinical Characterization of INCB 028050 Efficacious in Rodent Models of Arthritis : Selective Inhibition of JAK 1 and JAK 2 Is

J. Fridman, Jun Li, X. Wen, 2010 .

Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor

A. Gottlieb, P. Scherle, K. Vaddi, 2015, The British journal of dermatology.

Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.

J. Fridman, P. Scherle, C. Neilan, 2011, The Journal of investigative dermatology.

Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans

S. Shepard, J. Rodgers, T. Emm, 2010, Drug Metabolism and Disposition.

Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction.

S. Shepard, J. Rodgers, B. Metcalf, 2009, Organic Letters.